In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix 4C and commentary on the Company’s progress toward the first in-human clinical studies of its proprietary MagSense® technology.
View Imagion Biosystems December 2017 Quarterly Update.
The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging
October 17, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the